利培酮与舒必利治疗精神分裂症阴性症状Meta分析  

Meta-analysis of comparative study on the negative symptoms of schizophrenia treated with risperidone and sulpiride

作　　者：陶建青[1] 李伟生[1] 梁亚志[1] 刘佳斌[1] 冯昌生[1] 

机构地区：[1]广西壮族自治区人民医院心理康复中心,南宁530021

出　　处：《临床精神医学杂志》2008年第2期94-96,共3页Journal of Clinical Psychiatry

摘　　要：目的:采用Meta分析方法比较利培酮与舒必利治疗精神分裂症阴性症状的临床疗效。方法:将利培酮与舒必利治疗精神分裂症阴性症状的16个中文的随机对照研究进行再分析。结果:16个研究的合并效应量(WMD)为-0.58(-1.37,0.21;P>0.05)。阳性与阴性症状量表(PANSS)阴性因子(N)亚组的WMD为-0.84(-1.91,0.24;P>0.05);阴性症状评定量表(SANS)亚组的WMD为0.19,(-0.77,1.15;P>0.05)。结论:利培酮与舒必利对精神分裂症阴性症状的疗效无显著差别。Objective：To compare the efficacy of risperidone and sulpiride in treating the negative symptoms of schizophrenia by meta-analysis. Method：Sixteen randomized control study of risperidone and sulpiride published in Chinese were taken into meta-analysis. Results：Total effect size（weighted mean difference,WMD） of sixteen study was - 0.58,95% confidence interval （95% CI） was（ - 1.37,0.21 ; P 〉 0.05） ;WMD of negative subgroup of positive and negative symptom scale （PANSS-N） was - 0.84,95% CI was（ - 1.91,0.24; P 〉 0.05） ;WMD of score of the assessment of negative symptoms （SANS） sub-group was 0.19,95% CI was （-0.77,1.15,P〉0.05）. Conclusion：There are no significant difference between risperidone and sulpiride on efficacy of negative symptoms in the treatment of schizophrenia.

关 键 词：精神分裂症 阴性症状 利培酮 舒必利 META分析 

分 类 号：R749.3[医药卫生—神经病学与精神病学]